

Our Platform Optimized for Scale-up and Transfer (POSTmark™) consists of mirrored R&D and cGMP equipment, and process to enable:

- Support for all stages of development from R&D to cGMP scale
- cGMP LVV in 6-9 months
- Research grade LVV representative of cGMP LVV
- Reduce time, costs and risks

POSTmark™ was developed so that your first shot, is your best shot

POSTmark™ LVV
At-a-Glance

- cGMP LVV in 6-9 months
- Integrated cell therapy capabilities (CAR-T, CAR-NK, etc.) drive efficiencies & consolidated timelines
- Support for all stages of development from Benchtop R&D to cGMP scale
- Mirrored process/analytical development & cGMP unit operations supports IND-enabling materials
- Optimized for 3rd and 4th generation LVV plasmid platforms
- In house transient & packaging cell lines
- In house QC & fill/finish for both small and large volumes
- Customizable process & analytical development packages including potency assay development
- In house CMC Regulatory expertise and support including supporting health authority interactions, briefing books and module writing
- Our cGMP facilities, laboratories and processes have been developed and implemented to meet US FDA cGMP regulatory requirements including 21 CFR Parts 11, 210, 211, 610, and 1271; relevant US FDA Guidelines; and relevant ICH Quality Guidelines



R&D SUPPLY



4 - 8 WEEKS

GMP LVV



6 - 9 MONTHS

POSTmark™ LVV Platform


UPSTREAM

Expansion


Transfection

Clarification

Cell Viability



Population Doubling Level




DOWNSTREAM

Chromatography


Concentration & Formulation

Fill/Finish

Physical Titers



Infectious Titers



About Landmark Bio

Landmark Bio is a collective endeavor that brings together academia, industry, and hospitals to advance the development of transformative medicines. Founding members include Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc.

Landmark Bio provides end-to-end and process development, biomanufacturing capabilities and consulting services for life sciences innovators working on novel modalities such as cell, gene, and RNA medicines, and develop innovative manufacturing technologies to enable the advancement of novel therapies.

